CA2989145C - IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES - Google Patents

IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES

Info

Publication number
CA2989145C
CA2989145C CA2989145A CA2989145A CA2989145C CA 2989145 C CA2989145 C CA 2989145C CA 2989145 A CA2989145 A CA 2989145A CA 2989145 A CA2989145 A CA 2989145A CA 2989145 C CA2989145 C CA 2989145C
Authority
CA
Canada
Prior art keywords
methods
same
deferasirox
making
improved formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989145A
Other languages
English (en)
French (fr)
Other versions
CA2989145A1 (en
Inventor
Dave A Miller
Justin M Keen
Sandra U Kucera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DISPERSOL TECHNOLOGIES LLC
Original Assignee
DISPERSOL TECHNOLOGIES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DISPERSOL TECHNOLOGIES LLC filed Critical DISPERSOL TECHNOLOGIES LLC
Publication of CA2989145A1 publication Critical patent/CA2989145A1/en
Application granted granted Critical
Publication of CA2989145C publication Critical patent/CA2989145C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2989145A 2015-06-17 2016-06-17 IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES Active CA2989145C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17
US62/180,998 2015-06-17
PCT/US2016/038089 WO2016205658A1 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same

Publications (2)

Publication Number Publication Date
CA2989145A1 CA2989145A1 (en) 2016-12-22
CA2989145C true CA2989145C (en) 2024-10-29

Family

ID=57546755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989145A Active CA2989145C (en) 2015-06-17 2016-06-17 IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES

Country Status (10)

Country Link
US (4) US10265301B2 (enExample)
EP (1) EP3310354A4 (enExample)
JP (1) JP2018517734A (enExample)
CN (1) CN107847490A (enExample)
AU (3) AU2016280280B2 (enExample)
CA (1) CA2989145C (enExample)
HK (1) HK1254608A1 (enExample)
IL (1) IL256322B (enExample)
MA (1) MA43271A (enExample)
WO (1) WO2016205658A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565279B1 (en) 2007-12-05 2014-12-03 Complete Genomics, Inc. Efficient base determination in sequencing reactions
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN107267596A (zh) 2009-06-15 2017-10-20 考利达基因组股份有限公司 用于长片段阅读测序的方法和组合物
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
WO2020061474A1 (en) * 2018-09-20 2020-03-26 Tautona Group Ip Holding Company, L.L.C. Iron chelating compounds for treating aesthetic skin conditions
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205B (zh) * 2022-05-30 2023-03-28 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体
EP2590630B1 (en) * 2010-07-08 2015-04-29 ratiopharm GmbH Oral dosage form of deferasirox
WO2012025935A2 (en) * 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
BR112013007276A2 (pt) * 2010-10-01 2016-06-14 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
SI2964202T1 (sl) * 2013-03-08 2019-02-28 Novartis Ag Peroralne formulacije deferasiroksa
CN105377256A (zh) 2013-05-10 2016-03-02 奇普拉股份有限公司 低剂量药物组合物

Also Published As

Publication number Publication date
US11878005B2 (en) 2024-01-23
CN107847490A (zh) 2018-03-27
MA43271A (fr) 2018-09-26
AU2016280280A1 (en) 2018-01-04
US20170027911A1 (en) 2017-02-02
AU2021277731A1 (en) 2021-12-23
JP2018517734A (ja) 2018-07-05
US20190167643A1 (en) 2019-06-06
EP3310354A1 (en) 2018-04-25
US20170296514A1 (en) 2017-10-19
AU2024202528A1 (en) 2024-05-09
US20240091201A1 (en) 2024-03-21
AU2021277731B2 (en) 2024-04-11
CA2989145A1 (en) 2016-12-22
WO2016205658A1 (en) 2016-12-22
HK1254608A1 (zh) 2019-07-26
US10258608B2 (en) 2019-04-16
US10265301B2 (en) 2019-04-23
IL256322A (en) 2018-02-28
AU2016280280B2 (en) 2021-09-02
EP3310354A4 (en) 2018-12-12
IL256322B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CA2989145C (en) IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES
AU2017246458A1 (en) Cell-free production of ribonucleic acid
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
EP3270694A4 (en) Certain chemical entities, compositions, and methods
MY191581A (en) Anti-pd-1 antibodies
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3221391A4 (en) Swellable compositions, articles formed therefrom, and methods of manufacture thereof
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
EP4279071A3 (en) Novel cannabinoid formulations
CA3287905A1 (en) Compositions, cell constructs, and methods of making and using the same
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
SG10201909805XA (en) Surface modified polymer compositions
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
AU2014227660A8 (en) Ceftolozane antibiotic compositions
MY193444A (en) Cell-free production of ribonucleic acid
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
ZA201807446B (en) Improved drug formulations
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MY195399A (en) Mixed Decyl Mercaptans Compositions and Methods Of Making Same
AU2019366996A8 (en) Polymer-lipids and compositions
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520

EEER Examination request

Effective date: 20210520